65 research outputs found
The role of FDG-PET in Hodgkin lymphoma
No full text18-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) is currently the most valuable imaging technique in Hodgkin lymphoma. Since its first use in lymphomas in the 1990s, it has become the gold standard in the staging and end-of-treatment remission assessment in patients with Hodgkin lymphoma. The possibility of using early (interim) PET during first-line therapy to evaluate chemosensitivity and thus personalize treatment at this stage holds great promise, and much attention is now being directed toward this goal. With high probability, it is believed that in the near future, the result of interim PET-CT would serve as a compass to optimize treatment. Also the role of PET in pre-transplant assessment is currently evolving. Much controversy surrounds the possibility of detecting relapse after completed treatment with the use of PET in surveillance in the absence of symptoms suggestive of recurrence and the results of published studies are rather discouraging because of low positive predictive value. This review presents current knowledge about the role of 18-FDG-PET/CT imaging at each point of management of patients with Hodgkin lymphoma
Design of dual-processor level 2 terminal for CCITT common channel signalling system no.7
No full textThis thesis was scanned from the print manuscript for digital preservation and is copyright the author.
Researchers can access this thesis by asking their local university, institution or public library to
make a request on their behalf. Monash staff and postgraduate students can use the link in the References field
Prognostic value of bone marrow tracer uptake pattern in baseline PET scan in Hodgkin Lymphoma:results from an International Collaborative Study
No full textRATIONALE: Positron Emission Tomography/Computed Tomography (PET/CT)-ascertained bone marrow involvement (BMI) constitutes the single most important reason for upstaging by PET/CT in Hodgkin lymphoma (HL). However, BMI assessment in PET/CT can be challenging. This study analysed the clinico-pathological correlations and prognostic meaning of different patterns of bone marrow (BM)-Fluorodeoxyglucose (FDG)-uptake in HL.PATIENTS AND METHODS: 180 newly diagnosed early unfavourable and advanced stage HL patients, all scanned at baseline and after 2 Adriamycin-Bleomycin-Vinblastine-Dacarbazine (ABVD) courses with FDG-PET, enrolled in two International studies aimed at assessing the role of interim PET scan in HL, were retrospectively included. Patients were treated with ABVD x 4-6 cycles and involved-field radiation when needed, and no treatment adaptation on interim PET scan was allowed. Two blinded reviewers independently reported the scans.RESULTS: Thirty-eight patients (21.1%) had focal lesions (fPET+), 10 of them with a single (unifocal) and 28 with multiple (multifocal) BM lesions. Fifty-three (29.4%) had pure strong (> liver) diffuse uptake (dPET+) and 89 (48.4%) showed no or faint (≤ liver) BM uptake (nPET+). BM biopsy (BMB) was positive in 6/38 (15.7%) of fPET+, in 1/53 (1.9%) of dPET+ and in 5/89 (5.6%) of nPET+. dPET+ was correlated with younger age, higher frequency of bulky disease, lower hemoglobin levels, higher leucocyte counts and similar diffuse uptake in the spleen. Patients with pure dPET+ had an identical 3-year Progression Free Survival (3Y-PFS) to patients without any FDG uptake (82.9% and 82.2%, respectively P = 0.918). However patients with fPET+ (either unifocal or multifocal) had a 3-Y-PFS significantly inferior to patients with dPET+ and nPET+ (66.7% and 82.5%, respectively, P = 0.03). The kappa-values for inter-observer agreement were 0.84 for focal uptake and 0.78 for diffuse uptake.CONCLUSION: We confirmed that FDG-PET scan is a reliable tool for BMI assessment in HL and BMB is no longer needed for routine staging. Moreover, the inter-observer agreement for BMI in this study proved excellent and only focal FDG BM uptake should be considered as a harbinger of HL.</p
Therapy of relapsed and refractory plasma cell myeloma in Polish population – analysis
No full textThe treatment of relapsed and refractory plasma cell myeloma is a real challenge, especially in case of resistance to proteasome inhibitors and immunomodulatory drugs (IMiDs). The situation is complicated by the lack of commonly accepted therapeutic guidelines. This study summarizes therapeutic strategies used to treat recurrent plasma cell myeloma in Polish population before 2015, when bortezomib has become available in the first-line therapy. We focused mainly on the use of IMiDs and proteasome inhibitors. To analyze the situation medical records of patients treated in 21 Polish hematological centers have been reviewed. In total data on 400 patients were analyzed and extrapolated to the national level to obtain data on 7293 patients (400/7293). Mean number of applied therapies was 1.7. Half of the patients were treated with two or more chemotherapy regimens. Second-line therapy most commonly included: VD, PAD, thalidomide in monotherapy and MP regimen. Combinations of two drugs, namely lenalidomide, thalidomide or bortezomib with dexamethasone, were most often used in third-line therapy. Fourth-line treatment most commonly consisted of MPT regimen and dexamethasone monotherapy. At least PR was observed in 73%, 82%, and 50% of patients treated with II, III and IV-line therapy, respectively. Complications were observed in at least half of the patients regardless the type of treatment. Polyneuropathy and myelotoxicity were the most common adverse events.The outcome of recurrent plasma cell myeloma treatment in Polish patients was relatively good, probably because of rare use of bortezomib and lenalidomide in first-line therapy
A dissolute and promiscuous idyll. History and language in “The Abduction of Europe” by Krzysztof Koehler
No full textThe article is a reflection on Krzysztof Koehler’s poetic volume entitled Porwanie Europy [The Abduction of Europe] (2008). The author analyses the formal and
semantic aspects of the volume, the most important of which are: the collage of genres and content, the palimpsest of meanings, the antique tradition (including nautical motifs). Thanks to this reflection, one can notice that Koehler’s work starts from references to mythical and archetypal motifs in order to build a specific historiosophy and reach essential truths about man.IRENEUSZ STAROŃ, mgr, absolwent filologii polskiej Uniwersytetu Wrocławskiego. Przygotowuje monografię poezji Krzysztofa Koehlera. Wraz z Pauliną Subocz wydał książkę Nadkolory i nadaromaty. Schulz, Mueller, Blecher (Lublin 2017), traktującą o micie dzieciństwa w metafizycznych autobiografiach. Publikował m.in. w „Pamiętniku Literackim”, „Pracach Literackich”, „Toposie” i „Arcanach”. Współautor (z P. Subocz--Białek) monografii: Poza mapą. O „Nadberezyńcach” Floriana Czarnyszewicza (Kraków 2020).Uniwersytet WrocławskiDoświadczyłem Istnienia. Z Krzysztofem Koehlerem rozmawia Michał Larek, „Kresy” 2004, nr 1/2.Edwards M., Eliot/język, [w:] tegoż, Ku poetyce chrześcijańskiej, przeł. M. Szuba, red. nauk. J. Ward, M. Fengler, Gdańsk–Pelplin 2017.Heidegger M., Budować, mieszkać, myśleć, przeł. K. Michalski, „Teksty” 1974, nr 6.Heidegger M., Bycie i czas, przeł., przedmowa, przyp. B. Baran, Warszawa 1994.Koehler K., Na krańcu długiego pola i inne wiersze z lat 1988–1998, Warszawa 1998.Koehler K., Palus sarmatica, Warszawa 2016.Koehler K., Porwanie Europy, Sopot 2008.Koehler K., Progresywny klasycyzm, „Polonistyka” 2000, nr 2.Koehler K., Rzecz-pospolita to jest Rzym!, „Teologia Polityczna” 2015/2016, nr 8.Koehler K., Trzecia część, Kraków 2003.Lisowski K., Zgwałcona Europa, „Nowe Książki” 2009, nr 3.Łotman J.M., Dom w „Mistrzu i Małgorzacie” Michaiła Bułhakowa, przeł. R. Mazurkiewicz, „Pamiętnik Literacki” 1987, z. 4.Mikołajczak M., Wstęp, [w:] Z. Herbert, Wybór poezji, oprac. M. Mikołajczak, Wrocław 2018.Polkowski J., Oddychaj głęboko, Kraków 1981.Przybylski R., Klasycyzm czyli prawdziwy koniec Królestwa Polskiego, Warszawa 1983.Przybylski R., Słowo i milczenie Bohatera Polaków. Studium o „Dziadach”, Warszawa 1993.Sosnowski A., poems, Wrocław 2010.Schulz B., Opowiadania. Wybór esejów i listów, wstęp i oprac. J. Jarzębski, Wrocław 1989, BN I 264.Staroń I., Negatyw blasku. „Erinnerung” Krzysztofa Koehlera, „Metafora” 2017, nr 23.Staroń I., Pługiem przez skiby pamięci. Afazja i głębia w poezji Krzysztofa Koehlera, „Topos” 2018, nr 5.Szczot M., Dialog Palinura z Karonem wobec antycznej tradycji rozmów zmarłych, [w:] Biernat z Lublina a literatura i kultura wczesnego renesansu w Polsce, red. J. Dąbkowska-Kujko, A. Nowicka-Struska, Lublin 2015.W cieniu doświadczenia. Z Krzysztofem Koehlerem rozmawiają Jerzy Borowczyk i Wiesław Ratajczak, „Czas Kultury” 1994, nr 3.36538
A dissolute and promiscuous idyll. History and language in “The Abduction of Europe” by Krzysztof Koehler
No full textThe article is a reflection on Krzysztof Koehler’s poetic volume entitled Porwanie Europy [The Abduction of Europe] (2008). The author analyses the formal and
semantic aspects of the volume, the most important of which are: the collage of genres and content, the palimpsest of meanings, the antique tradition (including nautical motifs). Thanks to this reflection, one can notice that Koehler’s work starts from references to mythical and archetypal motifs in order to build a specific historiosophy and reach essential truths about man.IRENEUSZ STAROŃ, mgr, absolwent filologii polskiej Uniwersytetu Wrocławskiego. Przygotowuje monografię poezji Krzysztofa Koehlera. Wraz z Pauliną Subocz wydał książkę Nadkolory i nadaromaty. Schulz, Mueller, Blecher (Lublin 2017), traktującą o micie dzieciństwa w metafizycznych autobiografiach. Publikował m.in. w „Pamiętniku Literackim”, „Pracach Literackich”, „Toposie” i „Arcanach”. Współautor (z P. Subocz--Białek) monografii: Poza mapą. O „Nadberezyńcach” Floriana Czarnyszewicza (Kraków 2020).Uniwersytet WrocławskiDoświadczyłem Istnienia. Z Krzysztofem Koehlerem rozmawia Michał Larek, „Kresy” 2004, nr 1/2.Edwards M., Eliot/język, [w:] tegoż, Ku poetyce chrześcijańskiej, przeł. M. Szuba, red. nauk. J. Ward, M. Fengler, Gdańsk–Pelplin 2017.Heidegger M., Budować, mieszkać, myśleć, przeł. K. Michalski, „Teksty” 1974, nr 6.Heidegger M., Bycie i czas, przeł., przedmowa, przyp. B. Baran, Warszawa 1994.Koehler K., Na krańcu długiego pola i inne wiersze z lat 1988–1998, Warszawa 1998.Koehler K., Palus sarmatica, Warszawa 2016.Koehler K., Porwanie Europy, Sopot 2008.Koehler K., Progresywny klasycyzm, „Polonistyka” 2000, nr 2.Koehler K., Rzecz-pospolita to jest Rzym!, „Teologia Polityczna” 2015/2016, nr 8.Koehler K., Trzecia część, Kraków 2003.Lisowski K., Zgwałcona Europa, „Nowe Książki” 2009, nr 3.Łotman J.M., Dom w „Mistrzu i Małgorzacie” Michaiła Bułhakowa, przeł. R. Mazurkiewicz, „Pamiętnik Literacki” 1987, z. 4.Mikołajczak M., Wstęp, [w:] Z. Herbert, Wybór poezji, oprac. M. Mikołajczak, Wrocław 2018.Polkowski J., Oddychaj głęboko, Kraków 1981.Przybylski R., Klasycyzm czyli prawdziwy koniec Królestwa Polskiego, Warszawa 1983.Przybylski R., Słowo i milczenie Bohatera Polaków. Studium o „Dziadach”, Warszawa 1993.Sosnowski A., poems, Wrocław 2010.Schulz B., Opowiadania. Wybór esejów i listów, wstęp i oprac. J. Jarzębski, Wrocław 1989, BN I 264.Staroń I., Negatyw blasku. „Erinnerung” Krzysztofa Koehlera, „Metafora” 2017, nr 23.Staroń I., Pługiem przez skiby pamięci. Afazja i głębia w poezji Krzysztofa Koehlera, „Topos” 2018, nr 5.Szczot M., Dialog Palinura z Karonem wobec antycznej tradycji rozmów zmarłych, [w:] Biernat z Lublina a literatura i kultura wczesnego renesansu w Polsce, red. J. Dąbkowska-Kujko, A. Nowicka-Struska, Lublin 2015.W cieniu doświadczenia. Z Krzysztofem Koehlerem rozmawiają Jerzy Borowczyk i Wiesław Ratajczak, „Czas Kultury” 1994, nr 3.36538
P017: The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma
No full textCereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium
No full textCereblon (CRBN) is crucial for antiproliferative and immunomodulatory properties of immunomodulatory drugs. The objective of this study was to verify whether germline single nucleotide polymorphisms (SNPs) in the CRBN gene may influence response to lenalidomide in multiple myeloma (MM). Fourteen tagging SNPs covering the genetic variability in the CRBN gene region were genotyped in 167 Polish patients with refractory/relapsed MM treated with lenalidomide-based regimens. We found that carriers of minor alleles of two studied CRBN SNPs rs1714327G > C (OR = 0.26; 95% CI = 0.1-0.67; p = .0055, Bonferroni corrected p = .033) and rs1705814T > C (OR = 0.22; 95% CI = 0.07-0.65; p = .0063, Bonferroni corrected p = .037) were significantly associated with lower probability of achievement at least partial remission while treated with lenalidomide-based regimens, using the dominant inheritance model. Moreover, one of these SNPs, namely rs1705814T > C, was correlated with shorter progression-free survival (HR = 2.49; 95%CI = 1.31-4.74, p = .0054, Bonferroni corrected p = .033). It is suggested that selected germline CRBN allelic variants (rs1714327G > C and rs1705814T > C) affect lenalidomide efficacy in patients with relapsed/refractory MM
Długotrwała odpowiedź na leczenie brentuksymabem vedotin u pacjenta z nawrotem chłoniaka Hodgkina po auto-HSCT
No full textThe standard of care for patients with refractory or relapsed Hodgkin lymphoma is salvage chemotherapy followed by autologous hematopoietic stem cell transplantation. This method is not always effective, however. For patient who do not respond or those who relapse again treatment opportunities are limited. Before of the brentuximab vedotin ”era” the prognosis of such patients was poor, with a 5-year overall survival not exceeding 30%. Allogeneic stem cell transplantation (allo-HSCT) may be curative, but its success is highly dependent on prior good disease control. Brentuximab vedotin can be effective bridging treatment before allo-HSCT because 34% of patients can achive complete remission. In addition, in some patients, used as monotherapy without additional consolidation treatment allows for long-term responses.Standardowym postępowaniem w przypadku opornego na leczenie lub nawrotowego chłoniaka Hodgkina jest ratunkowa chemioterapia zakończona przeszczepieniem autologicznych krwiotwórczych komórek macierzystych. Jednak metoda ta nie zawsze jest skuteczna. W przypadku pacjentów, którzy nie reagują na tę formę leczenia lub u których dochodzi do kolejnego nawrotu, możliwości leczenia są ograniczone. Przed „erą” brentuksymabu vedotin rokowanie u takich chorych było bardzo złe, z 5-letnim całkowitym przeżyciem nieprzekraczającym 30%. Przeszczepienie allogenicznych krwiotwórczych komórek macierzystych (allo-HSCT) może spowodować wyleczenie, ale jego powodzenie jest silnie uzależnione od wcześniejszej dobrej kontroli choroby. Brentuksymab vedotin jest skutecznym leczeniem pomostowym przed allo-HSCT, ponieważ u 34% pacjentów pozwala uzyskać całkowitą remisję. Dodatkowo u części pacjentów, zastosowany w monoterapii bez dodatkowego leczenia konsolidującego, pozwala uzyskać długotrwałe odpowiedzi
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study
No full textEarly-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease
- …
